Rein Therapeutics, Inc. Operating Lease Cost
Rein Therapeutics, Inc. (RNTX) reported Operating Lease Cost of $184.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2024-04-15
- Rein Therapeutics, Inc. operating lease, cost for the quarter ending 2019-12-31 was $317.00K.
- Rein Therapeutics, Inc. operating lease, cost for the quarter ending 2019-09-30 was $317.00K.
- Rein Therapeutics, Inc. operating lease, cost for the quarter ending 2019-06-30 was $317.00K.
- Rein Therapeutics, Inc. operating lease, cost for the quarter ending 2019-03-31 was $317.00K.
- Rein Therapeutics, Inc. operating lease, cost for fiscal 2023 was $184.00K, a 47.20% increase from fiscal 2022.
- Rein Therapeutics, Inc. operating lease, cost for fiscal 2022 was $125.00K, a 34.41% increase from fiscal 2021.
- Rein Therapeutics, Inc. operating lease, cost for fiscal 2021 was $93.00K, a 91.51% decline from fiscal 2020.
- Rein Therapeutics, Inc. operating lease, cost for fiscal 2020 was $1.09M, a 13.58% decline from fiscal 2019.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $184.00K 10-K · filed 2024-04-15 | |||
| 2022-12-31 | $125.00K 10-K · filed 2024-04-15 | |||
| 2021-12-31 | $93.00K 10-K · filed 2023-03-20 | |||
| 2020-12-31 | $1.09M 10-K · filed 2022-03-28 | |||
| 2019-12-31 | $317.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $634.00K derived: sum of 2 quarters · filed 2020-03-30 | $951.00K derived: sum of 3 quarters · filed 2020-03-30 | $1.27M 10-K · filed 2020-03-30 |
| 2019-09-30 | $317.00K 10-Q · filed 2019-11-07 | $634.00K derived: sum of 2 quarters · filed 2019-11-07 | $950.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $317.00K 10-Q · filed 2019-08-06 | $634.00K 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $317.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |